On the Way for Patients with Prostate Cancer to the Best Use of PSMA

Finn Edler von Eyben; Glenn Bauman; Daniel S Kapp; Irene Virgolini; Giovanni Paganelli

doi:10.3390/ijms23052478

On the Way for Patients with Prostate Cancer to the Best Use of PSMA

Int J Mol Sci. 2022 Feb 24;23(5):2478. doi: 10.3390/ijms23052478.

Authors

Finn Edler von Eyben¹, Glenn Bauman², Daniel S Kapp³, Irene Virgolini⁴, Giovanni Paganelli⁵

Affiliations

¹ Center for Tobacco Control Research, Birkevej 17, 5230 Odense, Denmark.
² Department of Oncology, Schulich School of Medicine & Dentistry, Western University of Ontario, 1151 Richmond Street, London, ON N6A 3K7, Canada.
³ Department of Radiation Oncology, The Stanford University School of Medicine, Stanford, CA 94305, USA.
⁴ Department of Nuclear Medicine, University Hospital in Innsbruck, Anichstrasse 35, 6080 Innsbruck, Austria.
⁵ IRCCS-Istituto Romagnolo Studio Tumori (IRST) "Dino Amadori", Via Pietro Maroncelli 40, 47014 Meldola, Italy.

Abstract

In recent years, the prostate-specific membrane antigen (PSMA) has achieved a significant role in the diagnostics and treatments of patients with prostate cancer [...].

Publication types

Editorial

MeSH terms

Humans
Male
Prostate-Specific Antigen*
Prostatic Neoplasms* / diagnosis
Prostatic Neoplasms* / therapy

Substances

Prostate-Specific Antigen